What we found
The Federal Trade Commission has asked a federal court to hold dietary supplement provider Amare Global Holdings, its former Chief Science Officer and two others in contempt over allegations they violated an FTC order barring false, deceptive or unsubstantiated health claims. Earlier in the same month, the FTC sued the multilevel marketer and three individuals for misrepresenting to parents and other consumers that dietary supplements marketed for children and adults could treat, cure or mitigate conditions such as depression, anxiety and ADHD, and for misleading its seller recruits, called brand partners, about their potential earnings. According to the FTC, the products were promoted as "science backed" and "clinically proven" and as boosting neurotransmitters like serotonin and dopamine or lowering cortisol, while the agency alleges there is no competent and reliable scientific evidence supporting those claims. The FTC states that one study cited for a children's mood product used no placebo control group, included only 10 participants, and was co-authored by people with a direct monetary interest in the outcome, and that a second cited study compared end results without assessing baseline measurements. The FTC says the earlier 2005 order it accuses the parties of violating covers the former science officer and all persons or entities acting in active concert with him, and the agency is seeking compensatory damages for consumers in the full amount they paid for the products at issue. Before you buy any supplement sold as treating a mood, anxiety or attention condition, ask for the actual study — then check whether it had a placebo group, how many people were in it, and whether the sellers wrote it. These are allegations in a court filing and a pending contempt motion; the harvested FTC release does not state that a court has ruled, and we have no response from the company or the individuals named. Our harvested material does not say how many consumers bought the products, what they spent, or how the products were pitched to any individual buyer. LIVEFRAUD ALERTS is independent and not affiliated with the FTC or any company named here; brands are named only because an official source named them.
- Single official FTC press release, quoted directly, including named agency staff and linked court filing.
- Every claim sentence tracks wording the FTC itself used, including the specific study defects it alleges.
- Allegation stage only — the release describes a contempt motion and a lawsuit, not a court ruling, so the underlying conduct is unadjudicated.
- Reviewed by 2 models from independent houses.
THE RULE
Money risk is the price of supplements bought on health promises the FTC calls unsubstantiated, plus lost income for people recruited to sell them; health risk is relying on a product instead of care for depression, anxiety or ADHD.
What we don’t know
- Whether the court will grant the contempt motion or find any violation.
- How many consumers or brand partners were affected and how much money was paid.
- What the company and the named individuals say in response.
- Whether refunds or redress will ever reach buyers.
The bench — who voted
2 INDEPENDENT AI MODELS REVIEWED THIS. ALL 2: HIGH RISK.
The card names a count. Here are the seats behind it, with what each one said.
GROQopenai/gpt-oss-120b · HIGH
Finding adds that FTC is seeking compensatory damages for consumers, which is not present in the provided evidence row
OPENROUTERopenrouter/free · HIGH
The finding includes specific details about two cited studies (no placebo control, only 10 participants, co-authors with monetary interest; second study lacked baseline measurements) that are not present in the evidence row, which only states 'cited deeply flawed studies.'
DISSENT, PRESERVEDThe finding appears to accurately reflect the full FTC press release (which the evidence row summarizes), but based solely on the provided evidence row, the finding goes beyond what that row supports.
Reviewed by 2 independent models; all judged the finding to go beyond the evidence.
▼ Protocol & challenge record
Objection (high): Entity conflation between the two FTC actions. The contempt motion respondents are Amare Global, Shawn Talbott, Patrick Hintze and FORMER CEO Hiep Tran. The lawsuit filed earlier the same month names Amare Global, Talbott, Hintze and CURRENT CEO/majority shareholder David Chung. The draft's headline claim ('three individuals in contempt') and the finding's second sentence ('sued the multilevel marketer and three individuals') sit side by side with no signal that these are two different sets of three individuals. Any reader — and any downstream aggregator — will reasonably infer the same trio. That is a factual error about who is accused of what, and it implicates a sitting CEO in a contempt proceeding he is not named in, and a departed CEO in a lawsuit he is not named in. This is the single most serious defect in the draft.
Not resolved — preserved on the record.
Objection (medium): The draft never discloses that three of the four contempt respondents were not parties to the 2005 order. The order was Talbott's; Amare, Hintze and Tran are being reached through the 'all persons or entities in active concert or participation with him' clause. Whether they are in fact bound is precisely the contested legal question the court must decide, and the FTC's own Bureau Director's quote ('knew of Talbott's prior order') is an argument, not a finding. The finding sentence 'The FTC says the earlier 2005 order it accuses the parties of violating covers the former science officer and all persons or entities acting in active concert with him' gestures at this but does not tell the reader that the extension to the company and the two executives is disputed terrain.
Not resolved — preserved on the record.
Objection (medium): Source-to-claim stretch on the second study. The release says the authors 'compared the end results of the placebo and treatment groups without assessing each group's baseline measurements.' The draft drops 'placebo and treatment groups' and writes 'compared end results without assessing baseline measurements.' Read against the immediately preceding sentence about a study with 'no placebo control group,' the compression invites the inference that the second study also lacked a placebo arm. It did have one; the alleged flaw was different. Small edit, real distortion.
Resolved: Restore the source's specificity: '...and that a second cited study compared the end results of the placebo and treatment groups without assessing each group's baseline measurements.' Two added words, no length problem.
Objection (medium): The risk_line asserts harm as fact: 'plus lost income for people recruited to sell them.' The harvested row supports only that the FTC alleges brand partners were misled about POTENTIAL EARNINGS. No lost income is alleged, quantified or established anywhere in the source — the draft's own limitation sentence concedes there are no figures on what anyone paid. Stating lost income in the declarative risk line contradicts the piece's own limitations block.
Resolved: Rewrite the risk_line clause to track the allegation rather than assert harm: '...plus money and time put in by people recruited to sell them after what the FTC calls misleading claims about potential earnings.'
Objection (medium): Single-source dependency, and part of the finding is second-hand within that single source. The entire package rests on one press release. The sentence about the lawsuit (children/adults marketing, brand-partner earnings claims) is the contempt release's own one-paragraph summary of a different release that was not harvested. The confidence_reasons say 'Every claim sentence tracks wording the FTC itself used' — true, but that is a statement about faithful transcription, not about evidentiary breadth. 'High' confidence is defensible for 'the FTC filed these papers'; it is doing rhetorical work it hasn't earned for the substance.
Not resolved — preserved on the record.
Objection (low): Currency gap. The row is dated 2026-06-12 and describes a pending motion. There is no check for a subsequent docket event — a ruling, a stipulation, a withdrawal, a settlement. The limitation says only that 'the harvested FTC release does not state that a court has ruled,' which is a statement about the release, not about the world. Absence of a ruling in a same-day press release is not evidence of absence of a ruling now.
Resolved: Reword the limitation to be about the world, not the document: 'As of the June 12, 2026 FTC release, no court had ruled; we have not checked the docket since.'
Objection (low): Internal inconsistency on naming. The disclaimer says 'brands are named only because an official source named them,' yet the piece names the corporate entity while withholding all four individual names that the FTC itself published. The result is a story about 'three individuals' the reader cannot identify — which is also what makes OBJ-1's conflation invisible to the reader. Either name them (the official source did) or drop the individual count from the claim line.
Not resolved — preserved on the record.
Objection (low): Two directive_options are unusable and tonally wrong for a piece about children's mental-health marketing: 'Send this to any neurotransmitter you know' and 'Forward this to the neurotransmitters in your life.' They are not directives, they are jokes at the expense of the subject matter. 'ATTENTION: EVERYONE' in callout_options is a non-targeting placeholder. The selected callout and directive are fine; the option pool suggests weak generation discipline.
Not resolved — preserved on the record.
Objection (low): Entity-name precision. The release headline uses 'Amare Global'; the body uses 'Amare Global Holdings' and 'Amare.' The draft adopts 'Amare Global Holdings' as the legal entity throughout without corroboration from a filing or registry. With one source and no docket check, the exact named defendant entity is an assumption.
Not resolved — preserved on the record.
Objection (low): Omitted context that materially affects reader interpretation: the 2005 order arose from CortiSlim/CortiStress cortisol-control weight-loss claims. That the same individual is now alleged to be making cortisol-lowering claims again is the strongest and most legible fact in the release for a consumer audience, and the draft drops it entirely while keeping the more abstract 'lowering cortisol' phrase.
Resolved: Add one clause to the 2005-order sentence noting the prior case involved cortisol-based weight-loss and illness-prevention claims for CortiSlim and CortiStress. This is fully supported by the harvested row and is the highest-value context available.
Preserved dissent
ON THE RECORDThe draft misstates who is accused of what. The contempt motion names Amare Global, Talbott, Hintze and former CEO Hiep Tran. The lawsuit names Amare Global, Talbott, Hintze and current CEO and majority shareholder David Chung. The draft presents 'three individuals' in the contempt motion and 'three individuals' in the lawsuit in adjacent sentences with nothing to tell them apart. The plain reading is that they are the same three. They are not. This is not a nuance — it is the difference between saying a sitting chief executive is facing a contempt motion and saying he is not. If the desk publishes this without disambiguation, I want it on the record that I said so before it went out.
ON THE RECORDThe risk_line states 'lost income for people recruited to sell them' as an established consequence. Nothing in the harvested material establishes that any recruit lost any income. The FTC alleges misrepresentation about potential earnings. The draft's own limitations block says we have no figures on what anyone spent. A piece cannot concede in paragraph six that it does not know the losses and assert them in the risk line.
ON THE RECORD'Every claim sentence tracks wording the FTC itself used' is offered as a reason for high confidence. Fidelity to a press release is not evidentiary strength. It is one interested party's characterisation of its own filing, reproduced accurately. Accurate reproduction of an advocate's account is the floor, not the ceiling, and it should not be listed as though it were corroboration.
ON THE RECORDTwo of the four directive_options are neurotransmitter puns. This is a story about a company the FTC says told parents a supplement could treat their children's ADHD. Generating 'Send this to any neurotransmitter you know' as a candidate share line for that story reflects badly on the process even though it was not selected.
The sources
Official sourceFTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims2026-06-12
The FTC filed a contempt motion and a lawsuit alleging a supplement multilevel marketer and named individuals made unsubstantiated claims that products could treat depression, anxiety and ADHD, cited deeply flawed studies, and misled brand-partner recruits about earnings.
Authority: official. Retrieved 2026-08-21.
Limitation: An FTC press release describing pending allegations; no court finding, no defence response, and no figures on the number of buyers or total consumer losses.
Open the original source →Other checks
Published under standing founder pass (A9) — every claim source-mapped by the machine.
▼ What the machine checked
- ✓ Not a community submission.
- ✗ Draws on an FTC enforcement release, which names a defendant: "FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubs".
- ✓ All 5 material sentence(s) map to FTC.
- ✗ groq returned "overstated"; openrouter returned "overstated" — published on the receipt, not blocking (A9 amendment).
- ✓ No audience band is set.
No human affirmed these. They were verified by the classifier described in Amendment A9, on 2026-08-22.
Something wrong here? Tell us and we'll correct it — corrections are published, not quietly edited.
Phishy? Send it → sharelivefraud.com/squire-it
Not affiliated with any government agency, credit bureau, bank, platform, or law-enforcement agency. Informational only — not legal or financial advice.
Naming a source is not an endorsement, and being named here is not an accusation against any company.
Powered by SquireIt™
Verify this receipt at squireit.com